{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ00085",
      "entity_text" : "protein",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ04124",
      "entity_text" : "Meplazumab",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "By co-immunoprecipitation, ELISA, and immuno-electron microscopy, they show that anti-CD147 antibody (Meplazumab) could competitively inhibit the binding of spike protein (SP) with CD147 and thus prevent infection of target cells.",
  "reading_complete" : "2020-08-04T12:53:27Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T12:51:46Z",
  "trigger" : "inhibit",
  "evidence" : [ "Meplazumab) could competitively inhibit the binding of spike protein" ],
  "pmc_id" : "7350607",
  "score" : 0
}